What is Zacks Research's Forecast for Biogen Q2 Earnings?

Biogen Inc. (NASDAQ:BIIB - Free Report) - Zacks Research cut their Q2 2025 earnings per share estimates for Biogen in a report issued on Thursday, May 15th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings of $4.09 per share for the quarter, down from their prior forecast of $4.19. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen's Q3 2025 earnings at $3.85 EPS, Q4 2025 earnings at $3.67 EPS, FY2025 earnings at $14.64 EPS, Q1 2026 earnings at $3.42 EPS, Q3 2026 earnings at $3.74 EPS and Q4 2026 earnings at $3.68 EPS.

Other equities research analysts have also recently issued reports about the stock. The Goldman Sachs Group cut their price target on shares of Biogen from $219.00 to $197.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Truist Financial dropped their target price on Biogen from $210.00 to $199.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Robert W. Baird dropped their target price on Biogen from $300.00 to $255.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. HC Wainwright dropped their target price on Biogen from $241.00 to $187.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Finally, BMO Capital Markets dropped their price objective on Biogen from $156.00 to $139.00 and set a "market perform" rating on the stock in a research note on Thursday, February 13th. Twenty research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, Biogen currently has an average rating of "Hold" and an average price target of $191.30.

Biogen Stock Down 0.4%

Shares of BIIB stock traded down $0.49 during trading on Monday, reaching $125.81. The company's stock had a trading volume of 837,351 shares, compared to its average volume of 1,391,772. The business has a fifty day moving average price of $124.61 and a 200-day moving average price of $140.92. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.27. The company has a market cap of $18.43 billion, a price-to-earnings ratio of 11.24, a price-to-earnings-growth ratio of 1.51 and a beta of 0.12. Biogen has a one year low of $110.04 and a one year high of $238.00.

Biogen (NASDAQ:BIIB - Get Free Report) last released its earnings results on Thursday, May 1st. The biotechnology company reported $3.02 EPS for the quarter, missing the consensus estimate of $3.26 by ($0.24). The firm had revenue of $2.43 billion during the quarter, compared to the consensus estimate of $2.25 billion. Biogen had a net margin of 16.87% and a return on equity of 14.98%. The company's revenue was up 6.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.67 EPS.

Insider Transactions at Biogen

In other Biogen news, Director Stephen A. Sherwin sold 8,760 shares of the stock in a transaction on Friday, March 7th. The stock was sold at an average price of $150.02, for a total transaction of $1,314,175.20. Following the transaction, the director now owns 11,318 shares in the company, valued at $1,697,926.36. This trade represents a 43.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Biogen

A number of hedge funds have recently bought and sold shares of the business. Signaturefd LLC increased its holdings in shares of Biogen by 3.5% during the fourth quarter. Signaturefd LLC now owns 2,092 shares of the biotechnology company's stock worth $320,000 after purchasing an additional 71 shares during the period. Quent Capital LLC increased its stake in Biogen by 31.9% during the 4th quarter. Quent Capital LLC now owns 298 shares of the biotechnology company's stock worth $46,000 after acquiring an additional 72 shares during the period. Principal Securities Inc. increased its stake in Biogen by 30.1% during the 4th quarter. Principal Securities Inc. now owns 337 shares of the biotechnology company's stock worth $52,000 after acquiring an additional 78 shares during the period. Israel Discount Bank of New York increased its stake in Biogen by 6.2% during the 4th quarter. Israel Discount Bank of New York now owns 1,405 shares of the biotechnology company's stock worth $215,000 after acquiring an additional 82 shares during the period. Finally, Deseret Mutual Benefit Administrators increased its position in shares of Biogen by 5.7% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,612 shares of the biotechnology company's stock worth $247,000 after purchasing an additional 87 shares during the period. 87.93% of the stock is owned by institutional investors.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.